The stock has a 36-month beta value of 0.90. Opinions on the stock are mixed, with 10 analysts rating it as a “buy,” 4 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for SNDX is 81.08M, and at present, short sellers hold a 26.29% of that float. On January 15, 2025, the average trading volume of SNDX was 2.08M shares.
SNDX) stock’s latest price update
Syndax Pharmaceuticals Inc (NASDAQ: SNDX)’s stock price has gone decline by -1.56 in comparison to its previous close of 12.80, however, the company has experienced a -7.96% decrease in its stock price over the last five trading days. prnewswire.com reported 2025-01-13 that – Launched Revuforj® (revumenib) for treatment of R/R acute leukemia with a KMT2A translocation in adult and pediatric patients one year and older – – Revumenib added to NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)for AML and ALL – – Niktimvo™ (axatilimab-csfr) approved by U.S. FDA for treatment of chronic GVHD after failure of at least two prior lines of systemic therapy in adult and pediatric patients weighing at least 40 kg – – sNDA filing for revumenib in R/R mNPM1 AML expected in 1H25 based on positive pivotal data from AUGMENT-101 trial – WALTHAM, Mass., Jan. 13, 2025 /PRNewswire/ — Syndax Pharmaceuticals (Nasdaq: SNDX) will present at the 43rd Annual J.P.
SNDX’s Market Performance
SNDX’s stock has fallen by -7.96% in the past week, with a monthly drop of -11.45% and a quarterly drop of -34.13%. The volatility ratio for the week is 5.71% while the volatility levels for the last 30 days are 5.06% for Syndax Pharmaceuticals Inc. The simple moving average for the past 20 days is -5.47% for SNDX’s stock, with a -34.85% simple moving average for the past 200 days.
Analysts’ Opinion of SNDX
Many brokerage firms have already submitted their reports for SNDX stocks, with UBS repeating the rating for SNDX by listing it as a “Buy.” The predicted price for SNDX in the upcoming period, according to UBS is $37 based on the research report published on October 24, 2024 of the previous year 2024.
Jefferies, on the other hand, stated in their research note that they expect to see SNDX reach a price target of $37. The rating they have provided for SNDX stocks is “Buy” according to the report published on June 28th, 2024.
Scotiabank gave a rating of “Sector Perform” to SNDX, setting the target price at $23 in the report published on January 31st of the previous year.
SNDX Trading at -19.56% from the 50-Day Moving Average
After a stumble in the market that brought SNDX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -50.28% of loss for the given period.
Volatility was left at 5.06%, however, over the last 30 days, the volatility rate increased by 5.71%, as shares sank -6.46% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -33.40% lower at present.
During the last 5 trading sessions, SNDX fell by -7.96%, which changed the moving average for the period of 200-days by -45.38% in comparison to the 20-day moving average, which settled at $13.33. In addition, Syndax Pharmaceuticals Inc saw -4.69% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at SNDX starting from Goldan Keith A., who purchase 1,250 shares at the price of $20.03 back on Jun 14 ’24. After this action, Goldan Keith A. now owns 52,623 shares of Syndax Pharmaceuticals Inc, valued at $25,037 using the latest closing price.
Stock Fundamentals for SNDX
Current profitability levels for the company are sitting at:
- -19.43 for the present operating margin
- -1.7 for the gross margin
The net margin for Syndax Pharmaceuticals Inc stands at -17.96. The total capital return value is set at -0.88. Equity return is now at value -81.88, with -72.01 for asset returns.
Based on Syndax Pharmaceuticals Inc (SNDX), the company’s capital structure generated 0.0 points at debt to capital in total, while cash flow to debt ratio is standing at -303.12. The debt to equity ratio resting at 0.0. The interest coverage ratio of the stock is -1726.95.
Currently, EBITDA for the company is -229.94 million with net debt to EBITDA at 0.45. When we switch over and look at the enterprise to sales, we see a ratio of 57.05. The receivables turnover for the company is 3.53for trailing twelve months and the total asset turnover is 0.04. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.99.
Conclusion
To sum up, Syndax Pharmaceuticals Inc (SNDX) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
